Neuland Labs Names Saharsh Davuluri CEO, Boosting CDMO and Peptide Growth

Neuland Laboratories has announced a significant leadership change, appointing Saharsh Davuluri as its new Chief Executive Officer and Managing Director, effective April 1, 2026. Davuluri, who has spent over 18 years with the company, is set to lead Neuland's next growth phase. His focus will be on expanding commercial CDMO services and pursuing opportunities in New Chemical Entities (NCEs). This move follows strategic investments aimed at positioning Neuland as a premier global specialist in API process development and manufacturing.

Strategic Push into Peptides and CDMO Services

This leadership transition signals continuity and a strong internal promotion. Davuluri has been instrumental in building Neuland's CDMO business, and his new mandate is to drive expansion in high-growth areas like peptides, which are crucial for future revenue. Neuland aims to become a top-five global API CDMO, indicating a strategic move to capture more of the specialized pharmaceutical services market.

Building Peptide Capacity and Davuluri's Experience

Davuluri has played a key role at Neuland, leading its custom manufacturing solutions (CMS) business and managing marketing, IT, and business development. The company is heavily investing in its peptide manufacturing capabilities. A new commercial-scale peptide facility, the first of four planned modules, is scheduled to open by summer 2026, supported by roughly $30 million in customer commitments. This strategic expansion into peptides addresses rising global demand, especially for GLP-1 therapies, and aims to serve biotech and major pharma clients needing complex chemistry solutions.

Key Strategic Shifts

Davuluri's long tenure at Neuland ensures continuity and deep understanding of the company's strategic path. This leadership change signifies an accelerated focus on growing contract services revenue and expanding complex API and peptide manufacturing capabilities. The company is making tangible investments in new facilities, especially the commercial peptide plant, to meet anticipated demand, reinforcing its ambition to be a top-tier global API CDMO.

Potential Challenges

The company's future results depend on various risks and uncertainties, as outlined in its forward-looking statements. Successfully scaling the new peptide facility and securing ongoing customer commitments will be critical. Neuland must also maintain vigilance in quality and regulatory compliance, building on its good track record while addressing any past FDA observations. The API and CDMO sector remains competitive, requiring continuous innovation and efficiency.

Competitive Landscape

Neuland operates alongside major players in the API and CDMO sector, including Divi's Laboratories and Laurus Labs. Divi's is known for large-scale API manufacturing and custom synthesis, while Laurus Labs has expanded into CDMO and biotherapeutics. Neuland is carving out its specialized niche by focusing on complex peptides and NCEs.

Company Scale and Operations

Neuland operates three US FDA-inspected manufacturing facilities and a 40,000 sq. ft. R&D center. The company boasts 1218 KL of installed reactor capacity and holds over 20 commercial contracts for APIs and intermediates. Globally, Neuland has filed more than 1000 Drug Master Files (DMFs) and serves clients in over 80 countries.

Looking Ahead

Investors and analysts will monitor the rollout and capacity utilization of the new commercial peptide manufacturing facility. Success in securing new NCE contracts over the next one to two years will also be key. Updates on the development of the dedicated R&D process development center in Hyderabad and the overall growth of the CDMO segment compared to generic APIs will provide further insight.